Entrada Therapeutics (TRDA) Tax Provisions (2023 - 2026)

Entrada Therapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at $38000.0 for Q1 2026.

• In Q1 2026, Tax Provisions changed N/A year-over-year to $38000.0; the TTM figure through Mar 2026 stood at $992000.0 (up 206.67% YoY), while the FY2025 annual figure was $900000.0, up 4.77% from the prior year.
• Tax Provisions for Q1 2026 stood at $38000.0, down from $100000.0 in the prior quarter.
• The five-year high for Tax Provisions was $18.7 million in Q4 2023, with the low at -$17.4 million in Q3 2023.
• The 4-year median for Tax Provisions is $427000.0 (2025), against an average of $1.7 million.
• The sharpest annual moves came in 2024 and 2025: Tax Provisions sank 110.0% in 2024, then surged 135.16% in 2025.
• Entrada Therapeutics' Tax Provisions stood at $18.7 million in 2023, then tumbled by 110.0% to -$1.9 million in 2024, then soared by 105.35% to $100000.0 in 2025, then plunged by 62.0% to $38000.0 in 2026.
• Business Quant data shows TRDA's Tax Provisions at $38000.0 in Q1 2026, $100000.0 in Q4 2025, and $654000.0 in Q3 2025.